Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.78

0.0%

Dec 31 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mlkr who wrote (3025)	7/13/2010 1:46:04 PM
From: mlkr	of 3722

TBRN was $20 in 2007 with WYETH's back up which was bought by PFE: BY JONATHAN D. ROCKOFF AND PETER LOFTUS Pfizer Inc. is developing improved versions of top-selling biotechnology drugs, becoming the latest big drug maker to take aim at the biotech industry. Among its projects are three large molecules now in mid-stage development, according to Pfizer officials. Two of them aim to improve on Rituxan, a treatment for certain blood cancers and rheumatoid arthritis that is co-marketed by Roche Holding AG and Biogen Idec Inc. The third seeks to reduce how often medicines like Enbrel, a rheumatoid arthritis medicine that Pfizer co-markets with Amgen Inc., need to be injected. Pfizer bought Wyeth for $68 billion last year partly to ..

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next